The economic burden of posttransplant events in renal transplant recipients in Europe

Transplantation

Volumn 97, Issue 8, 2014, Pages 854-861

  Chamberlain, George ^a   Baboolal, Keshwar ^b   Bennett, Hayley ^a   Pockett, Rhys D ^a   McEwan, Phil ^a   Sabater, Javier ^c   Sennfält, Karin ^c  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cost; Europe; Glomerular filtration rate; Renal transplantation

Indexed keywords

ADULT; AGED; COST OF ILLNESS; DATABASES, FACTUAL; EUROPE; FEMALE; GLOMERULAR FILTRATION RATE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; QUESTIONNAIRES; RESOURCE ALLOCATION; RETROSPECTIVE STUDIES;

EID: 84899063658     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000438205.04348.69     Document Type: Article

References (29)

1. Bommer J. Prevalence and socio-economic aspects of chronic kidneydisease. Nephrol Dial Transplant 2002; 17 (Suppl 11): 8.
2. Henderson L. Future developments in the treatment of ESRD. A NorthAmerican perspective. Am J Kidney Dis 2000; 35(4 Suppl 1): S106.
3. Obrador GT, Mahdavi-Mazdeh M, Collins AJ. Establishing the GlobalKidney Disease PreventionNetwork (KDPN): a position statement fromthe National Kidney Foundation. Am J Kidney Dis 2011; 57 (3): 361.
4. White S, Chadban S, Jan S, et al. How can we achieve global equity inprovision of renal replacement therapy? Bull World Health Organ2008; 86: 229.
5. Grassmann A, Gioberge S, Moeller S, et al. ESRD patients in 2004:global overview of patient numbers, treatment modalities and associatedtrends. Nephrol Dial Transplant 2005; 20: 2587.
6. Zoccali C, Kramer A, Jager KJ. Chronic kidney disease and end-stagerenal diseaseVa review produced to contribute to the report 'thestatus of health in the European union: towards a healthier Europe'.NDT Plus 2010; 3: 213.
7. Baboolal K,McEwan P, Sondhi S, et al. The cost of renal dialysis in a UKsettingVa multicentre study. Nephrol Dial Transplant 2008; 23: 1982.
8. Kapoor A, Kwan KG, Whelan JP. Commercial renal transplantation: arisky venture? A single Canadian centre experience. Can Urol Assoc J2011; 5: 335.
9. Machnicki G, Lentine KL, Salvalaggio PR, et al. Three year posttransplantMedicare payments in kidney transplant recipients: associationswith pre-transplant comorbidities. Saudi J Kidney Dis Transpl2011; 22: 24.
10. Schnulle P, Lorenz D, Trede M, et al. The impact of renal cadaverictransplantation on survival in end-stage renal failure: evidence forreduced mortality risk compared with hemodialysis during long-termfollow-up. J Am Soc Nephrol 1998; 9: 2135.
11. Taylor A. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev OncolHematol 2005; 56: 23.
12. Kong Y,Wang D, Shang Y, et al. Calcineurin-inhibitor minimization inliver transplant patients with calcineurin-inhibitor-related renal dysfunction:a meta-analysis. PLoS One 2011; 6: e24387.
13. Bertelé V, Buonocore C, Michelacci F, et al. Efficacy and safety ofimmunosuppressive drugs approved in EU through the centralisedprocedure. Eur J Clin Pharmacol 2007; 63: 707.
14. Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantationExpert Opin Pharmacother 2008; 9: 635.
15. Woodroffe R, Yao GL, Meads C, et al. Clinical and cost-effectiveness ofnewer immunosuppressive regimens in renal transplantation: a systematicreview and modelling study. Health Technol Assess. 2005; 9:1, iiiYiv.
16. Jürgensen JS, Arns W, Hass B. Cost-effectiveness of immunosuppressiveregimens in renal transplant recipients in Germany: a modelapproach. Eur J Health Econ 2010; 11: 15.
17. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvementin renal allograft survival despite a marked decrease in acuterejection rates over the most recent era. Am J Transplant 2004; 4: 378.
18. Schnitzler MA, Johnston K, AxelrodD, et al. Associations of renal functionat 1-year after kidney transplantation with subsequent return to dialysis,mortality, and healthcare costs. Transplantation 2011; 91: 134719.
19. Lazzaro C, McKenchnie T, McKenna M. Tacrolimus versus cyclosporinein renal transplantation in Italy: cost-minimisation and costeffectivenessanalyses. J Nephrol 2002; 15: 580.
20. Niemczyk M, Nowak M, Pilecki T, et al. Economic evaluation ofsirolimus-based immunosuppressive regimens in kidney graft recipients.Transplant Proc 2006; 38: 74-7.
21. Chaib-Eddour D, Chaib-Eddour H, Malaise J, et al. Cost of renaltransplant in Belgium. Transplant Proc 2005; 37: 2819.
22. Hagenmeyer EG, Haussler B, Hempel E, et al. Resource use andtreatment costs after kidney transplantation: impact of demographicfactors, comorbidities, and complications. Transplantation2004; 77: 1545.
23. Zhang Q, Rothenbacher D. Prevalence of chronic kidney disease inpopulation-based studies: Systematic review. BMC Public Health2008; 8: 117.
24. Couchoud C, Bayat S, Villar E, et al. REIN registry A new approach formeasuring gender disparity in access to renal transplantation waitinglists. Transplantation 2012; 94: 513.
25. Jindal RM, Ryan JJ, Sajjad I, et al. Kidney transplantation and genderdisparity. Am J Nephrol 2005; 25: 474.
26. Baboolal K, McEwan P, Sondhi S, et al. The cost of renal dialysis in a UKsettingVa multicentre study. Nephrol Dial Transplant 2008; 23: 1982.
27. Mogyorosy Z, Smith PC. The Main Methodological Issues in CostingHealth Care ServicesVa Literature Review. York, UK: Centre forHealth Economics; 2005. 242 p. (CHE Research Paper).
28. Cost conversion websiteVCCEMGYEPPIYCentre Cost Converter.Accessed at: http://eppi.ioe.ac.uk/costconversion/default.aspx. AccessedMarch 2012.
29. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimateglomerular filtration rate from serum creatinine: a new predictionequation. Modification of Diet in Renal Disease Study Group.Ann Intern Med 1999; 130: 461.